Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
Latest Information Update: 25 May 2026
At a glance
- Drugs Tasadenoturev (Primary)
- Indications Acral lentiginous melanoma
- Focus Adverse reactions
Most Recent Events
- 27 Apr 2026 Planned End Date changed from 1 Jan 2029 to 30 Jan 2029.
- 06 Mar 2026 New trial record